SEPTERNA INC
SEPNNASDAQTrading Snapshot
- Day Range
- $42.40 – $45.05
- 52-Week Range
- $17.55 – $51.10
- Volume (shares)
- 380,134
- Avg Volume (shares)
- —
- Shares Outstanding
- 46.7M
- Next Earnings
- 2026-11-25
Fundamentals Snapshot
- Annual Revenue
- $46M
- Last Q Revenue
- $27M
- P/E Ratio
- -81.7
- P/S Ratio
- 20.8x
- EPS (TTM)
- $-0.54
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +36.7%
SEPTERNA INC
SEPN
StockOtter · stockotter.spaceAbout SEPTERNA INC
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares of Stock
Septerna, Inc. (NASDAQ: SEPN - Get Free Report) COO Elizabeth Bhatt sold 4,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $37.41, for a total
CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head Survey
Septerna (NASDAQ: SEPN - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of
Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)
Valneva (NASDAQ: VALN - Get Free Report) and Septerna (NASDAQ: SEPN - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of t
Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)
Septerna (NASDAQ: SEPN - Get Free Report) and WAVE Life Sciences (NASDAQ: WVE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 13,300 Septerna, Inc. $SEPN
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Septerna, Inc. (NASDAQ: SEPN) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. T
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company's commo